REDEFINE 11: a higher-dose follow-up Novo Nordisk has a higher-dose CagriSema trial (REDEFINE 11) running in parallel, expected to report in the first half of 2027
Despite its growing popularity in biohacking circles and advanced longevity practitioners, Epitalons long-term safety remains unclear: No large-scale toxicology or pharmacokinetic studies in humans have been published
Here's a practical comparison: The key difference: Semax and Selank are well-characterized with human data and are better starting points for most people
Storage, Handling, and Preparation Proper handling of cagrilintide peptide is essential for maintaining stability and ensuring consistent results in research settings
Directly stimulates the formation of new synaptic connections between neurons, increasing dendritic complexity, enhancing neural network density, and fundamentally expanding the brains information processing capacity
For long-term storage, keep at -20C